Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002313843 | SCV000738563 | likely pathogenic | Familial thoracic aortic aneurysm and aortic dissection | 2017-12-12 | criteria provided, single submitter | clinical testing | The c.1761+5G>A intronic variant results from a G to A substitution 5 nucleotides after coding exon 24 in the COL3A1 gene. This alteration has been reported in an individual with biochemically confirmed vascular Ehler-Danlos syndrome (vEDS, also known as type IV), and RNA analysis revealed exon skipping (Pepin MG et al. Genet. Med. 2014;16:881-8; personal communication from Collagen Diagnostic Laboratory). A likely pathogenic, functionally-validated splicing alteration at this nucleotide position (c.1761+5G>T) has also been associated with vEDS (Lee B et al. J. Biol. Chem. 1991;266:5256-9). This nucleotide position is highly conserved in available vertebrate species. This alteration is predicted by BDGP to abolish the native splice donor site, but is predicted to weaken (but not abolish) the efficiency of the native splice donor site by ESEfinder. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
Collagen Diagnostic Laboratory, |
RCV000087446 | SCV000120332 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |